SBLENDORIO GLENN 4
4 · AMICUS THERAPEUTICS, INC. · Filed Apr 27, 2026
Research Summary
AI-generated summary of this filing
Amicus Therapeutics (FOLD) Director Glenn Sblendorio Sells Shares
What Happened
- Glenn Sblendorio, a director of Amicus Therapeutics (FOLD), disposed of company securities on 2026-04-27 in connection with the company’s acquisition by BioMarin Pharmaceutical Inc.
- He sold 142,564 shares of common stock (including 20,414 restricted stock units that vested at closing) at $14.50 per share for total cash proceeds of $2,067,178.
- In addition, multiple stock options were cancelled and converted into cash payments (reported as derivative disposals with no per‑share price shown). All options were fully vested and vested in full on consummation of the merger.
Key Details
- Transaction date: 2026-04-27 (reported on Form 4 filed 2026-04-27).
- Priced sale: 142,564 shares @ $14.50 = $2,067,178.
- Derivative actions: several option cancellations (cash-out) and vested RSU vesting — option cash payment equals ( $14.50 - option exercise price ) × number of option shares (per filing).
- Shares owned after transaction: not specified in the provided filing.
- Filing timeliness: reported on the same date as the transaction; no late filing indicated in the filing excerpt.
Context
- This was a disposition tied to a corporate event (the merger), not an open-market sale — common in M&A transactions where equity awards and outstanding shares are cashed out or converted.
- The option-related entries are not purchases or exercises that increase share ownership; they reflect cancellation and cash settlement of vested options.
Insider Transaction Report
Form 4Exit
SBLENDORIO GLENN
Director
Transactions
- Disposition to Issuer
Common Stock
[F1]2026-04-27$14.50/sh−142,564$2,067,178→ 0 total - Disposition to Issuer
Stock Options (right to buy)
[F2][F3]2026-04-27−20,000→ 0 totalExercise: $6.71Exp: 2026-06-09→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Options (right to buy)
[F2][F3]2026-04-27−16,236→ 0 totalExercise: $8.60Exp: 2027-06-13→ Common Stock (16,236 underlying) - Disposition to Issuer
Stock Options (right to buy)
[F2][F3]2026-04-27−19,473→ 0 totalExercise: $12.00Exp: 2029-06-27→ Common Stock (19,473 underlying) - Disposition to Issuer
Stock Options (right to buy)
[F2][F3]2026-04-27−18,574→ 0 totalExercise: $12.81Exp: 2030-06-04→ Common Stock (18,574 underlying) - Disposition to Issuer
Stock Options (right to buy)
[F2][F3]2026-04-27−36,111→ 0 totalExercise: $10.71Exp: 2031-06-10→ Common Stock (36,111 underlying) - Disposition to Issuer
Stock Options (right to buy)
[F2][F3]2026-04-27−45,423→ 0 totalExercise: $8.55Exp: 2032-06-09→ Common Stock (45,423 underlying) - Disposition to Issuer
Stock Options (right to buy)
[F2][F3]2026-04-27−30,474→ 0 totalExercise: $12.62Exp: 2033-06-08→ Common Stock (30,474 underlying) - Disposition to Issuer
Stock Options (right to buy)
[F2][F3]2026-04-27−42,467→ 0 totalExercise: $10.27Exp: 2034-06-06→ Common Stock (42,467 underlying) - Disposition to Issuer
Stock Options (right to buy)
[F2][F4]2026-04-27−74,872→ 0 totalExercise: $5.96Exp: 2035-06-05→ Common Stock (74,872 underlying)
Footnotes (4)
- [F1]The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 122,150 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger).
- [F2]In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option.
- [F3]Each Option was fully vested.
- [F4]Each Option vested in full in connection with consummation of the Merger.
Signature
/s/ Christian Formica, Attorney-in-Fact|2026-04-27